Description: Recent Clinical Study Looked Into Benefits of D3 Supplementation for Certain Digestive Tract Cancers
Can Vitamin D3 Supplementation Benefit Digestive Tract Cancers Positive for p53 Mutations
A recent study published in JAMA Network Open by Kanno et al. looked at the potential benefits of vitamin D3 supplementation for digestive tract cancers positive for p53 mutations. This was a post hoc analysis of data from a 2019 randomized clinical trial by Urashima et al. that found no overall benefit of 2000 IU/day vitamin D3 on 5-year relapse-free survival in digestive tract cancers.
The original trial found no benefit of 2000 IU vitamin D3 daily on 5-year relapse-free survival.
- This new analysis looked at a subgroup with biomarkers indicating p53 mutations.
- In patients positive for p53 biomarkers who took vitamin D3, there was a 2.5-fold improvement in relapse or death compared to placebo.
- This corresponds to a 27% absolute risk reduction and number needed to treat of 4.
- Patients negative for p53 biomarkers had no significant benefit from vitamin D3.
- The authors conclude vitamin D3 may improve outcomes for digestive tract cancers positive for p53 mutations.
- They recommend future studies on vitamin D3 and cancer survival include p53 biomarker testing.
- Study conducted by Kanno et al, published in JAMA Network Open in 2023
- Post hoc analysis of 2019 randomized clinical trial by Urashima et al
- Looked at 2000 IU/day vitamin D3 for digestive tract cancers
- Focused on subgroup with p53 biomarkers indicating mutations